{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:02:24Z","timestamp":1789509744814,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:06:30Z","timestamp":1789506390000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estudio multic\u00e9ntrico de cladribina en esclerosis m\u00faltiple remitente-recurrente en pacientes mayores de 50 a\u00f1os"],"prefix":"10.1016","author":[{"given":"Maria Susana","family":"Fortes-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Herrero-Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pato-Pato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lorenzo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Mart\u00ednez L\u00f3pez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.farma.2026.07.002_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.farma.2026.07.002_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitezer","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.farma.2026.07.002_bb0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatment","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.farma.2026.07.002_bb0020","first-page":"343","article-title":"Cladribine in the treatment of relapsing multiple sclerosis","volume":"67","author":"Robles-Cedeno","year":"2018","journal-title":"Rev Neurol"},{"issue":"5","key":"10.1016\/j.farma.2026.07.002_bb0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.farma.2026.07.002_bb0030","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.farma.2026.07.002_bb0035","author":"Comisi\u00f3n Auton\u00f3mica Central de Farmacia y Terap\u00e9utica. Dictamen cladribina en esclerosis m\u00falltiple. P\u00e1gina web del SERGAS"},{"key":"10.1016\/j.farma.2026.07.002_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.msard.2018.10.097","article-title":"Cladribine tablets 35 mg\/kg is efficacious in patients aged above and below 45 years with relapsing multiple sclerosis in the clarity study","volume":"26","author":"Giovanonni","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.farma.2026.07.002_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.farma.2026.07.002_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123727","article-title":"Efficacy and safety of cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: a real-world study","volume":"478","author":"Piedrabuena","year":"2025","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.farma.2026.07.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200415","article-title":"The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation","volume":"12","author":"Guerra","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.farma.2026.07.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103490","article-title":"Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years","volume":"58","author":"Disanto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105830","article-title":"Safety of high efficacy therapies in older people with multiple sclerosis: a real-world evidence study","volume":"90","author":"Silva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing\u2013remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.farma.2026.07.002_bb0080","article-title":"High prevalence of fatigue in contemporary patients with multiple sclerosis","volume":"7","author":"Broch","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"10.1016\/j.farma.2026.07.002_bb0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/jnnp.2007.121129","article-title":"Longitudinal study of variations in and predictors of fatigue in multiple sclerosis","volume":"79","author":"Johansson","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.farma.2026.07.002_bb0090","article-title":"Real-world evidence from T\u00fcrkiye on cancer risk and treatment exposure in multiple sclerosis: a histopathology-verified, registry-based study","volume":"103","author":"\u00d6zt\u00fcrk","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106724","article-title":"The real-world efficacy of cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland - a follow-up study after four years of observation","volume":"103","author":"Rauma","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative review on the use of cladribine tablets as exit therapy for stable elderly patients with multiple sclerosis","volume":"13","author":"de Seze","year":"2024","journal-title":"Neurol Ther"},{"issue":"12","key":"10.1016\/j.farma.2026.07.002_bb0105","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1007\/s12325-025-03391-5","article-title":"Real-world perspectives on switching patients with multiple sclerosis from anti-CD20 therapy to cladribine tablets from USA-based advanced practice providers: a podcast","volume":"42","author":"Kutz","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.farma.2026.07.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106578","article-title":"Safety and efficacy of cladribine in patients discontinuing fingolimod due to elevated transaminase levels: the finclad study","volume":"101","author":"S\u00f6nmez","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.farma.2026.07.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106145","article-title":"De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: a pilot study","volume":"92","author":"Sacco","year":"2024","journal-title":"Mult Scler Relat Disord"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:06:34Z","timestamp":1789506394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S1130634326001716"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio multic\u00e9ntrico de cladribina en esclerosis m\u00faltiple remitente-recurrente en pacientes mayores de 50 a\u00f1os","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}